Beyond Outplacement: A Modern Model for Pharma & Biotech Workforce Transition

I've been thinking a lot about what happens after a layoff in pharma and biotech. Not the announcement itself. Not the severance package. Not the WARN notice.

What happens next.

For years, companies have relied on traditional outplacement programs to help displaced employees update their résumés, search for jobs, prepare for interviews, and navigate the logistics of finding their next role.

There is nothing inherently wrong with those services.

The problem is that the market they were designed for has changed. And in some cases, the more urgent question is whether valuable capability is walking out the door before anyone has stopped to consider where else it could create value.

That is a very different problem.

Consider someone who has spent 10 or 15 years inside one pharmaceutical company.

They may have deep expertise. They may be highly respected internally. They may have led launches, built teams, managed complex stakeholders, worked across functions, influenced strategy, or developed capabilities that were extremely valuable to the organization.

But much of that value existed within a specific context.

Their internal title meant something. Their network knew what they had accomplished. Their leaders understood the complexity behind the work. Their reputation traveled ahead of them.

Then the organization restructures. Suddenly, that context disappears.

Now they have to explain their value to an external market that may organize the same work differently, use different titles, prioritize different capabilities, or be moving in a different strategic direction altogether.

This is where I think we are underestimating the real challenge of workforce transition.

A Medical Affairs professional may have experience that could translate into Field Medical leadership, Medical Strategy, capabilities, scientific communications, evidence generation, launch planning, or another adjacent function.

Someone in Clinical Development may have valuable experience that crosses into Medical Affairs, operations, alliance management, or portfolio strategy.

A Market Access professional may sit at the intersection of evidence, policy, payer strategy, commercialization, and stakeholder engagement.

The challenge is that the next role is not always the obvious continuation of the previous title.

And the market itself is shifting.

Organizations are restructuring. Functions are being redesigned. AI is changing workflows. M&A is redistributing talent. Launch models are changing. Some capabilities are becoming more valuable while others are being absorbed, automated, consolidated, or moved elsewhere in the organization.

Public layoff announcements have slowed. Fierce Biotech reported 33 biopharma companies laying off employees or shutting down in the first quarter of 2026, followed by 17 companies announcing layoffs in the second quarter. But fewer announcements do not mean the underlying workforce reset is over. Fierce also notes that layoff rounds tied to larger, previously announced reorganizations are not included in its monthly tracker totals. (Fierce Biotech April 1, 2026)

Companies are still redesigning functions, changing operating models, consolidating capabilities, and making selective workforce decisions.

In that environment, telling someone to "apply to similar jobs" may actually prolong the transition. Because the first question should be: Where does this person's experience create value now?

Traditional outplacement often provides useful infrastructure: résumé support, job boards, career coaching, application tracking, interview preparation, networking guidance, and technology tools.

But infrastructure is not the same as strategy.

A job board cannot tell a former Medical Affairs leader whether the market is rewarding their operating experience, launch experience, therapeutic expertise, people leadership, or ability to build something from the ground up.

A résumé tool cannot determine whether someone is targeting one level too high, one level too low, or the wrong category of role entirely.

An AI tool can identify keywords. It may not understand why a title that sounds similar in two companies can represent very different responsibilities — or why a Medical Director role at a global company and a Medical Director role at a pre-commercial biotech can be functionally two different jobs that select for different capabilities and profiles.

And generalized coaching may not recognize the difference between how pharma hires a Medical Director, a Field Medical leader, a Clinical Development executive, or a Market Access strategist.

And every month spent pursuing the wrong strategy is not simply another month without a job. It is another month of delayed learning.

I think modern transition support should begin before the résumé.

That audit opens in two directions at once.

Those two questions belong together. They are rarely asked together.

This framework clarifies something important:

A company can legitimately need to eliminate a role and still be making a mistake if it assumes the capability attached to that role is no longer valuable.

Those are not contradictory statements.

That is exactly why the audit matters — and why it belongs earlier in the process than most organizations currently place it.

When a restructuring eliminates a role, it does not necessarily eliminate the capability.

A Field Medical leader may have capabilities relevant to launch planning or medical excellence. A Clinical Development professional may have strengths in cross-functional leadership or evidence strategy. A commercial leader may possess deep market knowledge that translates into an emerging strategic role.

But those connections are easy to miss when talent systems are organized around titles rather than capabilities.

The question may never get asked clearly enough, early enough, or with enough organizational perspective to connect the dots.

In a market where companies are simultaneously reducing headcount in some areas while trying to build new capabilities in others, that gap is more than a minor inefficiency.

It is a recurring and potentially preventable loss. Before we transition this person out, have we actually audited the capabilities we are losing?

When the answer to the capability audit points outward, the work becomes one of translation — mapping what someone can do onto a market that may name it differently, value it differently, or not immediately recognize it at all.

For every person in external transition, the first questions should be:

Where does this experience fit today? Which capabilities are transferable? Which roles are realistic? Where is demand growing or contracting? What parts of this person's background are being undervalued? Where are they relying too heavily on their previous context? Which companies, functions, or business models are most likely to value what they bring? What gaps will the market notice? What story do they need to tell differently?

Once that is understood, everything else becomes more precise.

The résumé becomes more precise. The LinkedIn profile becomes more precise. The networking strategy becomes more precise. The company list becomes more precise. Interview preparation becomes more precise.

The person stops trying to convince every employer that they are a fit and starts identifying the environments where their experience already solves a problem.

That is a very different transition experience.

Whether the path is internal redeployment or external market transition, there are execution mechanisms that determine how effectively the strategy moves.

TECHNOLOGY

Technology is one. AI can analyze companies, compare roles, identify market signals, compress research timelines, prepare professionals for interviews, and dramatically accelerate information gathering.

Those are real advantages. But the same limitation that applies to generic outplacement applies to technology: it optimizes for what it can measure. Keyword match to a job description. Title similarity. Years in a function.

Useful filters, yes, but are also poor proxies for the actual hiring question at senior levels, which is rarely just: "Can this person perform these tasks?"

It is much closer to: "Can this person solve the problem in front of us?"

Technology accelerates the search. Human judgment determines where to focus it.

COMMUNITY

Community is the other mechanism — and its value may be even more underestimated.

Someone in transition can go from being surrounded by colleagues, meetings, projects, and professional identity to navigating the market largely alone.

Their internal network may be strong. Their external network may have gone cold. But the deeper cost of isolation is informational, not only emotional.

People navigating the market alongside one another collect signals faster when they are in contact: what companies are actually asking for in interviews, which capabilities are appearing repeatedly across roles, which functions are expanding, which are consolidating, and where opportunities may be emerging.

That’s learning at scale.

The difference between a transition that moves relatively quickly and one that stretches for months is often not effort alone. It is the quality of the initial read on where the market places that person's value — and how quickly the strategy is corrected when that read is wrong.

There is a tendency to view outplacement primarily as a benefit for the employee leaving. It is. But the employer is not disconnected from what happens next.

Employees watch how colleagues are treated when they leave. Future candidates hear those stories. Former employees become alumni, customers, partners, competitors, referral sources, and sometimes future hires.

And leaders who remain are forming their own conclusions about what the organization values. A workforce reduction will never be a pleasant experience. But companies still have choices about how people experience the transition.

Not every organization can provide an enormous severance package. But meaningful transition support is another way of giving people something useful: clarity, direction, access, preparation, and a stronger path forward.

The more I look at what is happening across pharma and biotech, the less I think this is simply an outplacement problem.

It is a workforce transition problem.

That includes exits.

It also includes redeployment, capability mapping, talent mobility, market education, alumni relationships, and helping experienced people reposition themselves as the industry changes around them.

And perhaps the more interesting question is not: "What services should we give someone after a layoff?"

It is: "What would it look like to treat capability — not role — as the unit of analysis in a workforce transition?"

That is a much more strategic question. And I suspect it is one employers will need to get better at answering.